Inmune Bio Secures UK Regulatory Alignment for CORDStrom™ in RDEB, Paving Way for 2026 MAA
INMB sits 30% above its 52-week low of $1.09.
Summary
Inmune Bio received positive regulatory feedback from the UK MHRA for its CORDStrom™ drug in RDEB, establishing a clear path for a 2026 conditional market authorization application. This de-risks a key pipeline asset and is vital for the company's long-term prospects.
Key Events · Product Development and Regulatory · INMB
-
Regulatory Alignment Achieved
Inmune Bio received official meeting minutes from the UK MHRA, confirming written alignment on all questions for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB), covering CMC, non-clinical, and clinical evidence.
-
Clear Path to Market in UK
The regulatory alignment provides a clear roadmap for a planned 2026 UK Marketing Authorization Application (MAA) seeking Conditional Marketing Authorization for Ebstrocel™.
-
Clinically Meaningful Benefits Recognized
The MHRA recognized MissionEB Phase 2 data as demonstrating 'clinically meaningful symptomatic benefit,' particularly in pain and pruritus, for RDEB patients.
-
Guidance for Confirmatory Phase 3 and Future Submissions
MHRA provided constructive guidance on the confirmatory Phase 3 program, accepted capital-efficient non-clinical safety and manufacturing plans, and invited alternative statistical approaches for rare diseases. The company plans EU and US submissions in late 2026 or early 2027.
Analysis · INMB · Life Sciences
This 8-K announces that Inmune Bio has received official minutes from its pre-Marketing Authorization Application (pre-MAA) meeting with the UK MHRA, confirming alignment on all regulatory questions for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB). This provides a clear regulatory roadmap for a planned 2026 UK Conditional Marketing Authorization Application, significantly de-risking the path to market for this ultra-rare disease treatment. The MHRA's recognition of clinically meaningful symptomatic benefits from Phase 2 data is a strong positive signal, and the guidance on confirmatory trials and statistical approaches is constructive. This progress on a key pipeline asset is crucial for the company, especially given its previously disclosed going concern warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.